Urticaria

Cardiovascular·MeSH: Chronic Urticaria

Prevalence

5.0 / 100K

34 drugs in development·17 companies·4 clinical trials

Drug Pipeline by Phase

Approved(1)

Drug	Company
desloratadine	PERRIGO Co plc (PRGO)

Phase 3(13)

Drug	Company
Barzolvolimab (CDX-0159)	Celldex Therapeutics, Inc. (CLDX)
bgb-16673	BeOne Medicines Ltd. (ONC)
BGB-16673	BeOne Medicines Ltd. (ONC)
dupilumab	NOVARTIS AG (NVSEF)
dupilumab	Novartis AG (NVS)
JYB1904	ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
lou064	Novartis AG (NVS)
non sedating h1-antihistamine	Sanofi (SNY)
omalizumab	NOVARTIS AG (NVSEF)
omalizumab	Novartis AG (NVS)
Remibrutinib	Novartis AG (NVS)
remibrutinib dose a	Novartis AG (NVS)
remibrutinib dose b	Novartis AG (NVS)

Phase 2(11)

Drug	Company
ars-1	ARS Pharmaceuticals, Inc. (SPRY)
barzolvolimab	Celldex Therapeutics, Inc. (CLDX)
briquilimab	Jasper Therapeutics Inc. (JSPR)
csu lower dose treatment	InflaRx N.V. (IFRX)
evo756	Evommune, Inc. (EVMN)
intranasal epinephrine technology product candidates	ARS Pharmaceuticals, Inc. (SPRY)
lou064	Novartis AG (NVS)
oral evo756	Evommune, Inc. (EVMN)
oral evo756 300 mg qd	Evommune, Inc. (EVMN)
oral evo756 50 mg bid	Evommune, Inc. (EVMN)
zumilokibart	Apogee Therapeutics, Inc. (APGE)

Phase 1(4)

Drug	Company
ak006	Allakos Inc. (ALLK)
blu-808	Blueprint Medicines Corp (BPMC)
EDP-978	ENANTA PHARMACEUTICALS INC (ENTA)
thb001	Third Harmonic Bio, Inc. (THRD)

Preclinical(2)

Drug	Company
EPS-1421	ENANTA PHARMACEUTICALS INC (ENTA)
slrn-517	ACELYRIN, Inc. (SLRN)

Phase 4(3)

BioSniper tracks 34 drugs in development for Urticaria across 17 companies.

There are 4 clinical trials targeting Urticaria tracked by BioSniper.

The estimated prevalence of Urticaria is approximately 5.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.